argenx SE · ARGX · FY2025 Q3 · Calendar Q4 2025

argenx: VYVGART Growth Supports Broader Pipeline Push

The supplied analysis supports a constructive but execution-dependent thesis: strong VYVGART growth and prefilled-syringe adoption provide commercial momentum, while label expansions and pipeline readouts could broaden the opportunity. The key counterweights are clinical enrollment, regulatory approval, competition and manufacturing execution.

Reported Before market openNASDAQHealthcare $65.12B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $5.18 Consensus $4.37
EPS surprise +18.5% Reported versus consensus
Reported revenue $948.0M Consensus $1.28B
Revenue surprise -25.7% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -0.2% Event window
SPY move -1.1% Same window
Abnormal move +0.9% Stock minus SPY
Volume 2.6× Versus trailing sessions
Subsequent drift +11.2% Up to 20 sessions
ARGXSPY benchmark

Ask FN2 about ARGX FY2025 Q3

Transcript, numbers and history already loaded
Why did ARGX fall 0.2% after beating EPS estimates in FY2025 Q3?What changed in ARGX's guidance and outlook in FY2025 Q3?Give me the bull and bear case for ARGX after FY2025 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

The quarter's analysis emphasized VYVGART net sales above $1 billion, broader prefilled-syringe adoption, progress toward label expansion and a pipeline framed around five 2026 registrational readouts. Management also highlighted modestly higher operating expenses and continued manufacturing investment.

Guidance delta

Maintained; management outlined continued investment and multiple 2026 readouts without a reported change in guidance.

Key takeaways

  • Management reported VYVGART net sales of $1.13 billion, up 19% quarter over quarter and 96% year over year.
  • Prefilled-syringe adoption was identified as a primary growth driver for new patient and prescriber starts.
  • The company highlighted label-expansion work in seronegative and ocular myasthenia gravis.
  • Management cited five registrational readouts planned for 2026 and four new pipeline assets advancing into Phase I.
  • Operating expenses are expected to rise modestly while management highlighted a $4.3 billion cash balance.

Management priorities

  • Advance VYVGART label expansions in seronegative and ocular myasthenia gravis.
  • Progress Phase III programs and deliver the planned 2026 registrational readouts.
  • Advance ARGX-121, ARGX-213 and other pipeline assets.
  • Scale manufacturing through the Fujifilm collaboration and North Carolina facility.
  • Expand global supply and external collaborations.

Follow ARGX with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Company context

Snapshot as of publication

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates.…

Historical context

All ARGX earnings
-1.6%FY2026 Q3 · Calendar Q4 2026+8.6%FY2026 Q2 · Calendar Q3 2026-2.5%FY2025 Q4 · Calendar Q2 2026

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
RDY Dr. Reddy's Laboratories Limited FY2027 Q2 · Calendar Q4 2026 — -0.3% Dr. Reddy’s: Mix-led margin gains and semaglutide rollout
DGX Quest Diagnostics Incorporated FY2026 Q3 · Calendar Q4 2026 +4.5% +1.8% Quest Diagnostics: growth broadens, but PAMA remains a headwind
MEDP Medpace Holdings, Inc. FY2026 Q3 · Calendar Q4 2026 +9.0% -1.3% Medpace: Record awards lift backlog as 2026 outlook improves
MOH Molina Healthcare, Inc. FY2026 Q3 · Calendar Q4 2026 +12.7% +0.8% Molina reaffirms 2026 outlook as Florida contract scales

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the ARGX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-24T01:20:42.042674+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-24T01:20:42.038962+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-24. For educational purposes only; not investment advice.